Market capitalization | $84.19b |
Enterprise Value | $131.98b |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 10.55 |
EV/Sales (TTM) EV/Sales | 2.90 |
P/S ratio (TTM) P/S ratio | 1.85 |
P/B ratio (TTM) P/B ratio | 5.11 |
Dividend yield | 5.56% |
Last dividend (FY23) | $2.31 |
As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.
28 Analysts have issued a Bristol-Myers Squibb forecast:
28 Analysts have issued a Bristol-Myers Squibb forecast:
Mar '24 |
+/-
%
|
||
Turnover | 45,534 45,534 |
1%
1%
|
|
Gross income | 25,431 25,431 |
5%
5%
|
|
EBITDA | 17,454 17,454 |
11%
11%
|
EBIT (operating result) EBIT | 7,534 7,534 |
21%
21%
|
Net profit | -6,148 -6,148 |
184%
184%
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The firm offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.
Head office | United States |
CEO | Christopher Boerner |
Employees | 34,100 |
Founded | 1933 |
Website | www.bms.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.